Results 81 to 90 of about 15,943 (150)

Biologic dose escalation in inflammatory bowel disease in the United States. [PDF]

J Manag Care Spec Pharm
Chapman C, Vadhariya A, Bires N, Brady BL, Creveling T, Ross R, Evans KA, Panni T, Chan-Diehl FW, McGinnis K.   +9 more
europepmc   +1 more source

Vedolizumab as a successful treatment of CTLA-4-associated autoimmune enterocolitis [PDF]

, 2016
Baldin, F, Berger, CT, Bigler, M, Bignucolo, O, Burgener, AV, Daikeler, TD, Frede, N, Gabrysch, A, Gebbers, JO, Grimbacher, B, Heijnen, I, Hess, C, Higgins, R, Hou, TZ, Hruz, P, Jauch, A, Jeker, LT, Jeker, R, Kistner, A, Kämpe, O, Marquardsen, F, Mehling, M, Meienberg, F, Meyer, B, Navarini, AA, Padberg Sgier, BC, Recher, M, Sansom, DM, Schwab, C   +28 more
core  

Therapeutic Drug Monitoring of the Subcutaneous Formulations of Infliximab and Vedolizumab-Current Knowledge and Future Directions. [PDF]

J Clin Med
Massouridis B, Sparrow MP.
europepmc   +1 more source

Intestinal transcriptomic analysis and prediction of biomarkers associated with mucosal healing following vedolizumab treatment in ulcerative colitis using machine learning. [PDF]

BMC Gastroenterol
Ando K, Kashima S, Sakatani A, Konishi H, Maemoto A, Ito T, Taruishi M, Ishiguro K, Fujiya M.   +8 more
europepmc   +1 more source

Beyond the label: real-world gastrointestinal adverse events associated with vedolizumab - a decade of FAERS pharmacovigilance. [PDF]

Front Pharmacol
Zheng J, Qiu C, Zhang Z.
europepmc   +1 more source

Combination Therapy With Fecal Microbiota Transplantation and Vedolizumab for Induction of Remission in Ulcerative Colitis: An Open-Label Pilot Study. [PDF]

Inflamm Bowel Dis
Syed S, Moayyedi P, Kao D, Patel J, Marshall JK, Surette M, Narula N.   +6 more
europepmc   +1 more source

Retrospective Validation of Clinical Decision Support Tools for Predicting Effectiveness Outcomes in Inflammatory Bowel Disease Patients Treated with Vedolizumab. [PDF]

Pharmaceutics
de Klaver PAG, van Woerkens AMH, D'Agnolo HMA, Pierik MJ, Derijks LJJ.   +4 more
europepmc   +1 more source

Off-Label Ustekinumab and Vedolizumab in Pediatric Anti-TNFα Refractory IBD: Therapeutic Drug Monitoring Insights from a Case Series. [PDF]

Pharmaceuticals (Basel)
Cheli S, Mosini G, Battini V, Carnovale C, Radice S, Lebiu M, Cattoni A, Zuin G, Clementi E.   +8 more
europepmc   +1 more source

Comparative Risk of Serious Infections Associated With Treatment of Inflammatory Bowel Disease. [PDF]

Inflamm Bowel Dis
Khan N, Sundararajan R, Patel D, Patel M, Bahirwani J, Mahmud N.   +5 more
europepmc   +1 more source

Biological therapies for inflammatory pouch disorders: insights and outcomes from the RESERVO study of GETECCU. [PDF]

Ther Adv Gastroenterol
Mesonero F, Zabana Y, Fernández-Clotet A, Leo-Carnerero E, Caballol B, Núñez A, García MJ, Bertoletti F, Bastida G, Suris G, Casis B, Ferreiro-Iglesias R, Calafat M, Jiménez I, Miranda-Bautista J, Lamuela LJ, Fajardo I, Torrealba L, Nájera R, Sáiz-Chumillas RM, González-Partida I, Vicuña M, García-Morales N, Gutiérrez A, López-García A, Benítez JM, Rubín de Célix C, Tejido C, Brunet-Mas E, Hernandez-Camba A, Ferrer CS, Rodríguez-Lago I, Piqueras M, Castaño A, Ramos L, Sobrino A, Rodríguez-Grau MC, Elosua A, Montoro-Huguet MA, Baltar R, Huguet JM, Hermida B, Caballero-Mateos A, Sánchez-Guillén L, Bouhmidi A, Pajares R, Baston-Rey I, López-Sanromán A, Albillos A, Barreiro-de Acosta M.   +49 more
europepmc   +1 more source